NICE Continues To Ration Access To Kidney Cancer Medicines, Preventing Doctors From Providing The Best Possible Treatment Option For Each Patient
Article Date: 30 Apr 2009 – 1:00 PDT
Today the National Institute for Health and Clinical Excellence (NICE) announced the Final Appraisal Determination (FAD) for Nexavar® (sorafenib), Sutent® (sunitinib), Avastin® (bevacizumab) and Torisel® (temsirolimus) in advanced kidney cancer. NICE has not recommended sorafenib, bevacizumab and temsirolimus as first line treatment option for kidney cancer. Furthermore, it does not recommend sorafenib or sunitinib for second line treatment for renal cell carcinoma (RCC) patients.
More than 7,000 people in the UK are diagnosed with kidney cancer each year, of which 1,7001 will have the advanced form of the disease.
Remember, our population is aging. And with the very, very elderly, the costs go down, so that percentage should be falling, and it’s not. Second, the cost of care is growing by so much, so at the same percentage, it’s worth a lot more. So let’s go back to the issue of comparative effectiveness, which we’re supporting. That’s where that can have a big impact. It’s not only there, but that’s where the waste is. That’s where people are using technologies that really either don’t work at all or keep people alive for for very limited [time] and [at] very high cost.
Hospice is one option, but we do need take account of the cost — you know, I hate to say it, the cost-benefit of some of the things we do. And either we can do it directly, or we can do it by bundling the payments and let the delivery system deal with it. So it’s a combination of the delivery system dealing with it, or, and/or providing more information for people to make the right decisions, both for themselves and for the care.